To validate this hypothesis, we conducted a phase II trial with the mTOR inhibitor sirolimus in patients with advanced pancreatic cancer, integrating measurement of phospho-p70S6K activation as a predictor of response. The gene discussed is MTOR; the disease is familial pancreatic carcinoma.